Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 4
2005 5
2007 3
2009 1
2010 6
2011 2
2012 12
2013 11
2014 18
2015 13
2016 12
2017 7
2018 8
2019 9
2020 5
2021 9
2022 13
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J. Hurvitz SA, et al. Among authors: madhusudan s. Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7. Lancet. 2023. PMID: 36495879 Free article. Clinical Trial.
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Valle J, et al. Among authors: madhusudan s. N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721. N Engl J Med. 2010. PMID: 20375404 Free article. Clinical Trial.
Targeting DNA damage repair precision medicine strategies in cancer.
Brownlie J, Kulkarni S, Algethami M, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S. Brownlie J, et al. Among authors: madhusudan s. Curr Opin Pharmacol. 2023 Jun;70:102381. doi: 10.1016/j.coph.2023.102381. Epub 2023 May 4. Curr Opin Pharmacol. 2023. PMID: 37148685 Free article. Review.
Towards Personalized Management of Ovarian Cancer.
Algethami M, Kulkarni S, Sadiq MT, Tang HKC, Brownlie J, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S. Algethami M, et al. Among authors: madhusudan s. Cancer Manag Res. 2022 Dec 15;14:3469-3483. doi: 10.2147/CMAR.S366681. eCollection 2022. Cancer Manag Res. 2022. PMID: 36545222 Free PMC article. Review.
Selective Killing of BRCA2-Deficient Ovarian Cancer Cells via MRE11 Blockade.
Alblihy A, Ali R, Algethami M, Ritchie AA, Shoqafi A, Alqahtani S, Mesquita KA, Toss MS, Ordóñez-Morán P, Jeyapalan JN, Dekker L, Salerno M, Hartsuiker E, Grabowska AM, Rakha EA, Mongan NP, Madhusudan S. Alblihy A, et al. Among authors: madhusudan s. Int J Mol Sci. 2023 Jun 30;24(13):10966. doi: 10.3390/ijms241310966. Int J Mol Sci. 2023. PMID: 37446144 Free PMC article.
Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted.
Ali R, Aouida M, Alhaj Sulaiman A, Madhusudan S, Ramotar D. Ali R, et al. Among authors: madhusudan s. Int J Mol Sci. 2022 Jun 29;23(13):7241. doi: 10.3390/ijms23137241. Int J Mol Sci. 2022. PMID: 35806243 Free PMC article. Review.
135 results